Il Messaggiere - Johnson & Johnson temporarily halts Covid-19 vaccine output: report

NYSE - LSE
CMSC 0.57% 24.53 $
RIO -0.6% 63.06 $
SCS 0.24% 16.92 $
BCC -0.01% 82.385 $
RBGPF 0% 77.27 $
NGG 0.47% 71.215 $
RELX 0.86% 47.095 $
BCE 0.42% 23.53 $
BTI 0.37% 55.995 $
CMSD 0.18% 24.505 $
RYCEF -1.11% 15.33 $
JRI -0.55% 13.844 $
VOD -0.47% 11.715 $
BP -0.04% 34.415 $
AZN 0.52% 77.965 $
GSK 0.83% 40.385 $
Johnson & Johnson temporarily halts Covid-19 vaccine output: report
Johnson & Johnson temporarily halts Covid-19 vaccine output: report

Johnson & Johnson temporarily halts Covid-19 vaccine output: report

Johnson & Johnson has temporarily suspended production at a key plant manufacturing the Covid-19 vaccine, the New York Times reported Tuesday.

Text size:

The facility in the Dutch city of Leiden halted output late last year, according to the report, which cited people familiar with the decision.

J&J, without confirming or denying the report, said it has continued to fulfill delivery commitments, a company spokesman said.

The factory, which is currently making an experimental vaccine, is expected to resume production of the Covid-19 vaccine again in a "few" months, the Times reported.

J&J currently has "millions of doses of our Covid-19 vaccine in inventory," according to the J&J spokesman.

"We continue to fulfill our contractual obligations in relation to the Covax facility and the African Union," the company spokesman said.

J&J has projected sales of $3 billion to $3.5 billion in 2022 for its Covid-19 vaccine, much less than the $32 billion forecast by Pfizer for the same period.

But the J&J vaccine has been sought after in developing countries because, unlike other options, it does not require transportation at very cold temperatures. Also, the vaccine was originally billed as a single-shot inoculation.

Additional plants are being outfitted to make the vaccine, but production is not expected until late spring, the Times said.

A.Bruno--IM